




Available online at  
**ScienceDirect**  
[www.sciencedirect.com](http://www.sciencedirect.com)

Elsevier Masson France  
**EM|consulte**  
[www.em-consulte.com/en](http://www.em-consulte.com/en)



## EDITORIAL

# Editorial



The 2018 JHTA: a renewed success!

On 13 and 14 December 2018, the 38th *Journées de l'Hypertension Artérielle* (12th International Meeting of the French Society of Hypertension) took place at the Cité Universitaire de Paris.

After the success of the 2017 JHTA, we decided this year to stay again on the magnificent Paris campus of students from all over the world. You did approve this place!

The 2018 JHTA were marked by the presentation and discussion of the new American and European recommendations, both of which were much more rigorous in terms of the blood pressure threshold to be achieved! However, while the objective proposed by the recommendations of the French health authorities has so far been to achieve only blood pressure below 140/90 mm Hg, only half of hypertensive patients were under control. Since 2006, no decrease in the prevalence of hypertension has been observed in France, with still one out of three adults suffering from hypertension. In addition, no improvement in the screening and management of hypertension could be identified. In women, therapeutic care has even deteriorated over this period. The CNAM also confirms the decrease in the number of antihypertensive drugs, in their cost but unfortunately, accompanied by an increase in cardiovascular complications and their related costs... There is an urgent need to defend, publish and inform people about this disease, which kills more than 10 million people worldwide each year.

This congress was in line with previous congresses with conferences, practical workshops (cardiac ultrasound and doppler ultrasound of the renal arteries, central pressure and pulse wave velocity, management of erectile dysfunction in hypertensive patients), point of care and numerous symposia this year demonstrating the vitality of this congress thanks to the promising results of new molecules in diabetes and dyslipidaemia but also in non-drug techniques. After the success of the "clinical cases" session last year, the best cases were discussed again in a friendly atmosphere. A "crossover" session between clinicians and researchers focused on hypertensive heart disease. We had even more joint sessions with other scientific societies: nephrology, endocrinology, CNCF, GERS, FFC, pharmacists (SFPC), Swiss HTA society. The abstracts of the presented works are presented below.

An excellent year, see you in 2019 for an even richer edition.

## Disclosure of interest

The author has not supplied his declaration of competing interest.

Atul Pathak\*, for the Organization, Administration Committee  
*Unité d'Hypertension Artérielle, Facteurs de Risque et Insuffisance Cardiaque,*  
*Inserm 1048 and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists),*  
*Clinique Pasteur, 31000 Toulouse, France*

\* Corresponding author.

E-mail address: [apathak@clinique-pasteur.com](mailto:apathak@clinique-pasteur.com)